AVELUMAB vs DOSTARLIMAB

Hey everyone! To give some context, I'm a registered nurse in Texas pursuing my MSN and, subsequently, Ph.D. I'm still trying to figure things out, but I'm interested in the research aspects of nursing and want to contribute to my field. As I go through the literature, mainly through the Emergency N

Hi, I’m [Dr. Due Diligence](https://linktr.ee/doctorduediligence), and I’m starting a weekly series where I am looking at the top shorted biotech stocks in the world to try and find value. I have worked in the clinic, academia, and for biotech startups before switching to investing full time. My inv

#**$KURA – Kura Oncology** **Overview:** Kura Oncology was created in 2007 and is based in California. The company is utilizing the genomic revolution to transform how cancer is treated, understanding that a patient’s response to treatment depends partially on the cancer’s genetic makeup. With an

I get a lot of messages asking about my cancer, so before I get to my story: I highly recommend visiting [BCAN.org](http://BCAN.org) and asking to be paired up in their survivor to survivor program. Every diagnosis is different and the survivor to survivor program pairs you with someone with simila

Just want to re-iterate. I'm not a prophet. Not a teacher. I don't speak in front of live audiences. I have zero out of body experiences. No dreams. It's just me here. I'm like you, studying it. Everything I say is how I interpret it. If you're reading this, then, it's up to you to balance,

Here is another long look at the past couple of years. Take it as you may. This is a discussion, not a declaration of truth. This is an interpretation of what we know via statement and a hypothetical assembly of those words into what may be behind them. Let's try to put it together the way it cou

I copied here for convenience, the PR of 11/22/22: # "CytoDyn to Host R&D Update on Wednesday, December 7, 2022 VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- **CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist w

I know I put out a post yesterday, but for the sake of consistency, I did not want a Sunday to pass without a signature post. I'm not yet ready to break that trend. So here you go. But, I am pleased to see more and more posters. In [last week's post](https://www.reddit.com/r/Livimmune/comments/1g

I’m starting carboplatin/paclitaxel and dostarlimab for endometrial cancer on Feb 18th. It will be 6 infusions every three weeks with the immunotherapy continuing every 6 weeks for 3 years if all goes as planned. My oncologist stated that most of her patients continue to work through chemo. I’m a fi

Hi Guys, I am Jon 39 from Germany. I was diagnosed with Lynch syndrome with an advanced rectal tumor at the age of 21. Cancer has been with my family for generations; my grandfather died of colon cancer at the age of 36 and my mother died at the age of 57. Since my diagnosis in 2007 and neoadjuvant

The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. The announcement came as the Trump administration unveiled agreements with E

# Pipeline Development Acrivon Therapeutics specializes in oncology through its Acrivon Predictive Precision Proteomics (AP3) platform, which identifies compound-specific protein signatures to predict patient response. While the company positions AP3 as a repeatable discovery engine, it currently re